Stereotactic ablative radiotherapy (SABR) is superior to observation for preventing disease progression in men with recurrent hormone-sensitive oligometastatic prostate cancer, according to results from the phase II ORIOLE trial. Fifty-four patients were randomly allocated (2:1) to receive SABR or undergo observation. The primary outcome measure was progression at 6 months, defined by PSA increase, conventional imaging, symptomatic progression, initiation of androgen deprivation therapy or death. Progression occurred in 19% of patients receiving SABR compared with 61% undergoing observation (P = 0.005), and SABR improved median progression-free survival compared with observation (not reached vs 5.8 months; HR 0.30, 95% CI 0.11–0.81; P = 0.002).
References
Original article
Phillips, R. et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2020.0147 (2020)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Thomas, T. SABR improves outcomes in men with recurrent oligometastatic prostate cancer. Nat Rev Urol 17, 256 (2020). https://doi.org/10.1038/s41585-020-0321-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-020-0321-0